Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial

Yunpeng Yang, Wenfeng Fang, Nong Yang et al.|Signal Transduction and Targeted Therapy|2023

Cited by 32